Biocept NRAS Liquid Biopsy Test

Biocept has launched a new Target Selector liqud biopsy assay for mutations in the NRAS oncogene. According to the company, the NRAS mutations targeted by the test are associated with multiple cancer types such as metastatic melanoma, colorectal and lung cancer. The new test, like Biocept's other clinical assays, is run in its CLIA-certified San Diego lab. The new product brings the company's total number of Target Selector tests to 15.